Product Images Pemetrexed Disodium

This is a label for Pemetrexed, an injectable medication for intravenous use only. It comes in a single-dose vial and has a specific NDC number. The rest of the text is not available due to quality issues.*

The text describes a medication named Pemetrexed for Injection, USP used for intravenous use only. The medication comes in a single-dose vial containing 500 mg of pemetrexed disodium and 500 mg of mannitol, which needs to be reconstituted by adding 20 mL of 0.9% Sodium Chloride Injection. After reconstitution, the infusion solution must be further diluted before use. The solution must be refrigerated at 2° to 8°C before and after use. The medication is a cytotoxic agent, and the accompanying literature must be consulted before use. The text also displays manufacturer details and license numbers.*

This appears to be a table or graph presenting results from a medical study comparing treatment arm outcomes over a period of time. The treatments being compared are PesPrC (not defined) and Pe+C (pemetrexed + pembrolizumab + platinum chemotherapy) versus Pes (pemetrexed + platinum chemotherapy + placebo). The y-axis appears to show Overall Sunival (%) percentages ranging from 0-30, and the x-axis displays time in months. The table also lists the number of patients at risk for each treatment arm at different intervals.*

This appears to be a table of patient data in the context of cancer treatment options. Two treatment options are listed, Pemetrexed + Cisplatin (PC) and Gemitabine + Cisplatin (GC). The numbers in the first row and two columns likely correspond to the patients' survival times (in months) and the number of patients who were still being monitored at each interval. It is not possible to determine additional information from this specific text excerpt.*

This is a survival probability chart for two chemotherapy treatments for cancer: Pemetrexed + Cisplatin (PC) and Gemcitabine + Cisplatin (GC). The chart displays the percentage of patients who survive over time in months (on the x-axis) and the percentage of patients at risk (on the y-axis). The data is broken down into intervals of 10 months, starting from 0 to 30 months. The chart shows that patients who receive PC have a higher survival probability, especially in the first 10 months compared to those who receive GC treatment. The number of patients at risk decreases as the survival time increases.*

Survival Probability graph shows the comparison of the efficacy of Pemetrexed to Placebo in terms of survival time (months) for patients. The graph shows that Pemetrexed has better survival rates than Placebo. The number of patients at risk is also shown on the graph.*